ORPHA:98837
Acute biphenotypic leukemia
Is anyone studying this?
249
249 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
249 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
103 in the last 10 years · low confidence
Is a treatment being tested?
39
trials for this specific condition
39 interventional trials matched this specific condition name; 8 currently recruiting in our sample.
Data as of 26 July 2026
39 interventional trials — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 94.5th percentile).
low confidence · 94.5th percentile (trials denominator)
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Who's working on it?
1,398
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Huang F6 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 02Sun J6 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 03Xuan L6 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 04Fan Z5 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 05Xu N5 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 06Liu H4 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 07Liu Q4 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. liuqifa628@163.com.
Papers in Europe PMC - 08Wang Y4 papers · 2022
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Papers in Europe PMC - 09Zhang Y4 papers · 2025
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Papers in Europe PMC - 10Zhou H4 papers · 2024
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
39 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT02727803·Personalized NK Cell Therapy in CBT
- NCT07710781·Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
- NCT04797767·Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- NCT03326921·HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- NCT04047641·Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT02115295·Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT03683433·Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- NCT03779854·Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Acute biphenotypic leukemia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acute biphenotypic leukemia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 39 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
0Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low